source
- Two biotechs raise a combined $556M in latest spurt of IPOsSeaport Therapeutics and Hemab Therapeutics on Thursday became the latest drugmakers to debut on Wall Street, continuing a stretch of large IPOs this year that collectively raised almost $3.2 billion.BioPharma Dive · 3mo ago↗ source
- FDA's oncology advisors vote against 'new paradigm' in AstraZeneca trialIn its first meeting in about nine months, the FDA’s advisory committee of oncology experts voted 6-3 Thursday that a late-stage trial for AstraZeneca’s oral SERD camizestrant didn't show a “clinic…Endpoints · 3mo ago↗ source
- Krazati fails confirmatory trial in colorectal cancer, putting approval at riskBristol Myers Squibb’s cancer drug Krazati has failed its confirmatory study in second-line colorectal cancer, a company spokesperson confirmed to Endpoints News. Krazati had received accelerated a…